TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
TVRD
180 hedge funds and large institutions have $368M invested in Tvardi Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 49 increasing their positions, 56 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
180
Holders Change
+12
Holders Change %
+7.14%
% of All Funds
2.78%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
36
Increased
49
Reduced
56
Closed
23
Calls
$5.9M
Puts
$3.2M
Net Calls
+$2.7M
Net Calls Change
-$747K
Top Buyers
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$5.2M |
| 2 |
Renaissance Technologies
New York
|
+$4.4M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.36M |
| 4 |
JPMorgan Chase & Co
New York
|
+$2.67M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.16M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16M |
| 2 |
Jane Street
New York
|
-$2.38M |
| 3 |
Goldman Sachs
New York
|
-$2.2M |
| 4 |
Morgan Stanley
New York
|
-$1.16M |
| 5 |
Two Sigma Advisers
New York
|
-$1.05M |
